ABOUT RISEN
Risen Group
Corporate Culture
Development History
R&D Manangement Team
Partners
R&D
PIPELINE
NEWS
Company news
IP granted
Publications
CONTACT US
繁体
简体
RISEN PHARMA
ABOUT RISEN
Risen Group
Corporate Culture
Development History
Management Team
Partners
R&D
PIPELINE
NEWS
Company news
IP granted
Publications
CONTACT US
Company news
IP granted
Publications
2025-05-06
Risen Pharma Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting
Details
Year:
All
2025
2024
2023
2022
2021
2020
2025-05-06
Risen Pharma Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting
Detail
2024-12-23
Congratulations to Risen for being listed on the "Hurun Global Cheetahs Index 2024"
Detail
2024-12-09
Congratulations to Risen and its chairman Jiasheng Lv, Ph.D. for being listed on the (Baoding International Medical Base · Hurun China Healthcare Pioneering Young Start-ups 2024)and(Baoding International Medical Base ·
Detail
2024-11-13
PI3K-α inhibitor RP903 tablets have been approved for two additional PROS pediatric rare disease clinical trials.
Detail
2024-11-13
Risen Pharma and Maiwei Biotech have signed a licensing agreement to jointly promote the development of drugs in the field of bone health.
Detail
2024-11-13
Risen Pharma has entered into a comprehensive strategic cooperation agreement with the Shanghai Center for Infectious Diseases and Immune Innovation.
Detail
上一页
1
2
3
下一页
Shanghai Zhangjiang R&D Center.
Suzhou Industrial Park R&D Center.
send mail
Copyright 2022 Risen(Shanghai) Pharma Tech Co., Ltd. All Rights Reserved
沪ICP备16020731号-1
Design by:
yushangweb